The company outperformed when it last reported, so why has the CSL share price been languishing?

CSL has been stuck in the mud. What;s next?

| More on:
A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have failed to go anywhere for months now 
  • That's despite what was a well-received earnings report back in February 
  • So what's next for CSL? 

The CSL Limited (ASX: CSL) share price has been a bit of a disappointing investment in 2022 thus far. As it stands today, CSL shares are currently down 9.42% year to date. That includes the rather nasty 1.05% haircut we've seen so far today, which currently puts CSL at $268.12. 

What might be even more disappointing for CSL investors though is the cool off we've seen since the ASX 200 healthcare giant reported its half-year earnings back in February. CSL dropped its numbers on 16 February. These were exceedingly well received at the time, evidenced by the CSL share price's 14% rise between 15 and 17 February.

However, investor sentiment has cooled since then. At today's share pricing, CSL is now more than 3% off of those highs reached on 17 February.

So what's possibly gone awry at CSL that has caused this seeming share price malaise? 

Why can't the CSL share price get out of neutral?

Well, unfortunately, we can't say for sure. The company hasn't really given investors any major news since its earnings report, apart from a minor update to its ongoing quest to acquire the Swiss biotech company Vifor Pharma. But that doesn't seem to have had much of an impact on CSL shares then or since.

But what we do know is that one expert ASX investor is eyeing off what she sees as a bargain. Writing in the Australian Financial Review (AFR) today, Jun Bei Liu of Tribeca Investment Partners, calls CSL a quality company that investors have still chosen to sell off. She noted how the CSL share price "outperformed expectations by over 10 per cent" at its earnings, so questions why its shares have fallen since then. That's despite what she describes as an "exceptionally defensive global growth profile".

Ms Liu estimates that CSL will "deliver in excess of 20 per cent returns" this year, here's why:

As we move through the market uncertainty and geopolitical conflicts, confidence will return, and quality names will be the first to close the valuation gap.

At the current CSL share price, this ASX 200 health care share has a market capitalisation of $130.52 billion. 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »